1MITROV1C V, WILLENBROCK R, MIRIC M, et al. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure[J]. Am Heart J, 2003, 145(3): E14.
2SAKATA Y, YAMAMOTO K, MASUYAMA T, et al. Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart-failure[J]. J Hypertens, 2001,19(10): 1905-1912.
3FENTON C, SCOTT LJ. Candesartan cilexetil: a review of its use in the management of chronic heart failure[J]. Drugs, 2005,65(4): 537-558.
4MATSUMORI A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure[J]. Eur J Heart Fail, 2003,5(5) : 669-677.
6MELIAN EB, JARVIS B. Candesartan cilexetil plus hydrochlorothiazide combination:a review of its use in hypertension[J]. Drugs, 2002, 62(5): 787-816.
7PFEFFER MA, SWEDBERG K, GRANGER CB, et of. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme[J]. Lancet,2003, 362(9386): 759-766.
8McMURRAY JJ, OSTERGREN J, SWEDBERG K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial[J]. Lancet,2003, 362(9386): 767-771.
9GRANGER CB, McMURRAY JJ, YUSUF S, et ol. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial[J]. Lancet, 2003, 362(9386): 772-776.
10YUSUF S, PFEFFER MA, SWEDBERG K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial[J].Lancet, 2003, 362(9386): 777-781.
